期刊
HUMAN MUTATION
卷 21, 期 3, 页码 277-284出版社
WILEY
DOI: 10.1002/humu.10190
关键词
hematological cancer; tumor; p53; TP53; drug resistance; leukemia; lymphoma
Inactivation of the wild,type p53 gene (TP53) by various genetic alterations is a major event in human tumorigenesis. More than 60% of human primary tumors exhibit a mutation in the p53 gene. Hematological. malignancies present a rather low incidence of genetic alterations in this gene (10-20%). Nevertheless, epidemiological studies of the hematological. malignancies indicate that the prognosis of patients with A mutation in the p53 gene is worse than those expressing the wild-type p53 protein. Correlations between drug resistance, altered apoptosis, and mutations in the p53 gene are found in hematological malignancies and leukemias. These issues, as well as the possibility of exploiting p53 and its various functions for new therapeutic strategies, are discussed in the present review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据